NO20075145L - Farmakokinetisk forbedrede forbindelser - Google Patents

Farmakokinetisk forbedrede forbindelser

Info

Publication number
NO20075145L
NO20075145L NO20075145A NO20075145A NO20075145L NO 20075145 L NO20075145 L NO 20075145L NO 20075145 A NO20075145 A NO 20075145A NO 20075145 A NO20075145 A NO 20075145A NO 20075145 L NO20075145 L NO 20075145L
Authority
NO
Norway
Prior art keywords
improved compounds
pharmacokinetically improved
pharmacokinetically
compounds
rock2
Prior art date
Application number
NO20075145A
Other languages
English (en)
Inventor
Siya Ram
Paul Sweetnam
Stewart Campbell
Alessandra Bartolozzi
Hope Foudoulakis
Brian Kirk
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of NO20075145L publication Critical patent/NO20075145L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Foreliggende oppfinnelse angår inhibitorer av ROCK1 og ROCK2 og metoder for å modulere de farmakokinetiske og/eller farmakodynamisk egenskapene til slike forbindelser. Også gitt er metoder for å inhibere ROCK1 og/eller ROCK2 som er anvendelig for behandling av sykdom. ?? ?? ?? ?? 1
NO20075145A 2005-03-25 2007-10-10 Farmakokinetisk forbedrede forbindelser NO20075145L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66516505P 2005-03-25 2005-03-25
PCT/US2006/011271 WO2006105081A2 (en) 2005-03-25 2006-03-27 Pharmacokinetically improved compounds

Publications (1)

Publication Number Publication Date
NO20075145L true NO20075145L (no) 2007-11-28

Family

ID=37054004

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075145A NO20075145L (no) 2005-03-25 2007-10-10 Farmakokinetisk forbedrede forbindelser

Country Status (21)

Country Link
US (6) US8357693B2 (no)
EP (1) EP1865958B1 (no)
JP (2) JP2008534518A (no)
KR (1) KR20080081122A (no)
CN (1) CN101208094B (no)
AU (1) AU2006230159A1 (no)
BR (1) BRPI0622285A2 (no)
CA (1) CA2602254C (no)
CR (1) CR9465A (no)
EA (1) EA022875B1 (no)
EC (1) ECSP077836A (no)
ES (1) ES2549397T3 (no)
GE (1) GEP20105029B (no)
IL (1) IL186299A0 (no)
MX (1) MX2007011859A (no)
NO (1) NO20075145L (no)
NZ (1) NZ562083A (no)
SG (1) SG155163A1 (no)
UA (1) UA96126C2 (no)
WO (1) WO2006105081A2 (no)
ZA (1) ZA200708858B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093273B2 (en) 2004-10-20 2012-01-10 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
KR101431279B1 (ko) 2005-07-29 2014-08-20 리스버로직스 코퍼레이션 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달
US20090247519A1 (en) 2006-04-26 2009-10-01 Tony Michael Raynham Amino-ethyl-amino-aryl (aeaa) compounds and their use
JP2010501577A (ja) * 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物
WO2008069976A2 (en) 2006-12-01 2008-06-12 President And Fellows Of Harvard College Compounds and methods for enzyme-mediated tumor imaging and therapy
ES2454966T3 (es) 2007-02-01 2014-04-14 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
EP2132177B1 (en) * 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
EP2163258A1 (en) * 2007-06-19 2010-03-17 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
RU2520098C2 (ru) 2008-06-26 2014-06-20 Ресверлоджикс Корп. Способы получения производных хиназолинона
JP5412519B2 (ja) 2008-09-02 2014-02-12 ノバルティス アーゲー キナーゼ阻害剤としてのピコリンアミド誘導体
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
EP2406236A4 (en) * 2009-03-09 2013-07-24 Surface Logix Inc INHIBITORS OF RHO KINASE
NZ595747A (en) 2009-03-18 2015-06-26 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
SG11201407546QA (en) 2012-05-21 2014-12-30 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2013191244A1 (ja) * 2012-06-21 2013-12-27 大正製薬株式会社 ピリドピリミジン－４－オン誘導体
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
PL3035936T3 (pl) 2013-08-23 2019-08-30 Neupharma, Inc. Pewne jednostki chemiczne, kompozycje i sposoby
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
JP6480025B2 (ja) * 2015-06-24 2019-03-06 日東電工株式会社 イオン性化合物及び組成物並びにその使用
US10508106B2 (en) 2015-11-25 2019-12-17 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
US10544106B2 (en) 2016-08-15 2020-01-28 Neupharma, Inc. Certain chemical entities, compositions, and methods
US11071735B2 (en) 2017-04-28 2021-07-27 Kadmon Corporation, Llc Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
JP7039802B2 (ja) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
WO2019000682A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CA3063616A1 (en) 2017-06-30 2019-12-06 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
CA3073956A1 (en) 2017-09-03 2019-03-07 Angion Biomedica Corp. Vinylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
DK3749669T3 (da) 2018-02-06 2023-06-06 Ideaya Biosciences Inc Ahr-modulatorer
JP7187575B2 (ja) 2018-04-18 2022-12-12 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
CN112969694B (zh) * 2018-11-09 2023-06-13 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
JP7252417B2 (ja) 2019-10-18 2023-04-04 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法
WO2021129589A1 (zh) * 2019-12-27 2021-07-01 广东东阳光药业有限公司 Kd-025的新晶型及其制备方法
CN116390918A (zh) * 2020-07-22 2023-07-04 梯瓦制药国际有限责任公司 Belumosudil和belumosudil盐的固态形式
WO2022042666A1 (zh) * 2020-08-28 2022-03-03 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
WO2022170864A1 (zh) * 2021-02-09 2022-08-18 苏州科睿思制药有限公司 Belumosudil甲磺酸盐的晶型及其制备方法和用途
CN114573566B (zh) * 2021-03-04 2023-05-30 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
EP4370205A1 (en) 2021-07-16 2024-05-22 Sandoz Ag Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt
WO2023205153A1 (en) 2022-04-19 2023-10-26 Kadmon Corporation, Llc Belumosudil for treating chronic lung allograft dysfunction
WO2024000060A1 (en) * 2022-06-30 2024-01-04 Apotex Inc Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease
CA3178077A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Methods of administering belumosudil in combination with cyp3a inducers and/or proton pump inhibitors
CA3178096A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of chronic graft versus host disease
WO2024015068A1 (en) 2022-07-14 2024-01-18 Kadmon Corporation, Llc Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease
CA3178086A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations
CN115385899B (zh) * 2022-09-08 2024-04-02 药康众拓(江苏)医药科技有限公司 ROCK2抑制剂belumosudil的氘代药物及用途
WO2024063770A1 (en) 2022-09-21 2024-03-28 Kadmon Corporation, Llc Liquid formulation of belumosudil
WO2024100601A1 (en) 2022-11-11 2024-05-16 Assia Chemical Industries Ltd. Solid state forms of belumosudil and processes for preparation thereof
WO2024118556A1 (en) 2022-11-29 2024-06-06 Kadmon Corporation, Llc Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
WO2024124084A1 (en) 2022-12-09 2024-06-13 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of multiple myeloma

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT836605E (pt) * 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
ATE359822T1 (de) 1996-08-12 2007-05-15 Mitsubishi Pharma Corp Medikamente enthaltend rho-kinase inhibitoren
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
SI1270570T1 (sl) * 2000-03-16 2006-10-31 Mitsubishi Pharma Corp Amidne spojine in njihova uporaba
EP1270577B1 (en) * 2000-03-23 2006-12-06 Takeda Pharmaceutical Company Limited Furoisoquinoline derivatives, process for producing the same and use thereof
US6699665B1 (en) 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
DK1370552T3 (da) * 2001-03-23 2007-05-07 Bayer Pharmaceuticals Corp Rho-kinase-inhibitorer
CA2441492C (en) * 2001-03-23 2011-08-09 Bayer Corporation Rho-kinase inhibitors
AU2002327385A1 (en) 2001-07-27 2003-02-17 Surface Logix, Inc. Resealable and sealable devices for biochemical assays
EP1560939A4 (en) 2001-08-27 2007-04-25 Surface Logix Inc IMMOBILIZATION OF BIOLOGICAL MOLECULES ON SURFACES COATED WITH MONOSLAYS
JP2003221386A (ja) * 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
DE10162435A1 (de) 2001-12-19 2003-07-17 Joerg Lahann Verfahren zur Erzeugung von Oberflächenbeschichtungen, die die Adsorption von Proteinen bzw. die Adhäsion von Bakterien und/oder Zellen vermindern
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
AU2003298611A1 (en) * 2002-11-21 2004-06-18 Eli Lilly And Company Mixed lineage kinase modulators
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
US20050014783A1 (en) * 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EP1644003A1 (en) * 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
EP1663204B1 (en) * 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
ATE525377T1 (de) * 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
EP1848437A4 (en) * 2005-02-18 2012-04-25 Surface Logix Inc METHOD FOR PRODUCING PHARMACOKINETIC IMPROVED COMPOUNDS WITH FUNCTIONAL RESTORATIONS OR GROUPS AND PHARMACEUTICAL COMPOSITIONS WITH THESE COMPOUNDS
CN102351862A (zh) * 2005-02-18 2012-02-15 表面线段公司 药动学改善的化合物
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
JP2010501577A (ja) * 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物

Also Published As

Publication number Publication date
CA2602254A1 (en) 2006-10-05
US8916576B2 (en) 2014-12-23
CR9465A (es) 2008-06-19
SG155163A1 (en) 2009-09-30
CA2602254C (en) 2015-03-24
JP2008534518A (ja) 2008-08-28
US20100144707A1 (en) 2010-06-10
US20190177311A1 (en) 2019-06-13
WO2006105081A2 (en) 2006-10-05
US9440961B2 (en) 2016-09-13
CN101208094A (zh) 2008-06-25
US20130131047A1 (en) 2013-05-23
CN101208094B (zh) 2014-10-15
EA022875B1 (ru) 2016-03-31
MX2007011859A (es) 2008-04-04
JP2015193639A (ja) 2015-11-05
ECSP077836A (es) 2008-01-23
EA200702048A1 (ru) 2008-04-28
JP5956661B2 (ja) 2016-07-27
ZA200708858B (en) 2009-09-30
NZ562083A (en) 2010-12-24
AU2006230159A1 (en) 2006-10-05
EP1865958A4 (en) 2012-01-25
EP1865958B1 (en) 2015-07-08
US20210017166A1 (en) 2021-01-21
GEP20105029B (en) 2010-06-25
ES2549397T3 (es) 2015-10-27
KR20080081122A (ko) 2008-09-08
IL186299A0 (en) 2008-01-20
EP1865958A2 (en) 2007-12-19
WO2006105081A3 (en) 2007-05-10
BRPI0622285A2 (pt) 2011-08-16
US20150344464A1 (en) 2015-12-03
UA96126C2 (ru) 2011-10-10
US10570123B2 (en) 2020-02-25
US20180072710A1 (en) 2018-03-15
US8357693B2 (en) 2013-01-22

Similar Documents

Publication Publication Date Title
NO20075145L (no) Farmakokinetisk forbedrede forbindelser
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
NO20075099L (no) Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
NO20076401L (no) Diarylhydantoinforbindelser
NO20081636L (no) FAP - inhibitorer
NO20080963L (no) Piperidinyl-substiuerte isokinolinderivater som Rho-kinaseinhibitorer
WO2009073153A3 (en) Small molecule myristate inhibitors of bcr-abl and methods of use
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
MX2007010272A (es) Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
TW200621721A (en) Methods of preparing indazole compounds
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
CY1113443T1 (el) Παραγωγα πυριδαζινονης
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
NO20076515L (no) Hydantoinforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application